Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Crawford

Foot and Ankle Surgery Irving, TX Medical Doctor

NPI 1255530002 CMS profile 283528

2001 N MacArthur Blvd, Suite 255, Irving, TX 75061

Open in the dashboard

General payments

$63,385

135 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Crawford of Irving, TX is reported in the CMS Open Payments database as having received $63,385 across 135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $550 20
2024 General $28,924 16
2023 General $21,056 20
2022 General $6,885 9
2021 General $1,373 13
2020 General $2,850 21
2019 General $1,747 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Crawford
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Adam Crawford were reported at $550. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Adam Crawford Foot and Ankle Surgery median Middle half National median
2019 $1,747 $1,327 $279–$5,421 $163
2020 $2,850 $795 $121–$3,473 $114
2021 $1,373 $1,289 $201–$4,963 $132
2022 $6,885 $1,539 $270–$6,067 $149
2023 $21,056 $1,117 $257–$5,264 $160
2024 $28,924 $1,064 $235–$4,944 $164
2025 $550 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Trilliant Surgical LLC. $53,880 11 payments
  2. Arthrex, Inc. $3,023 15 payments
  3. Pylant Medical $2,569 13 payments
  4. Anika Therapeutics, Inc. $1,019 3 payments
  5. Wright Medical Technology, Inc. $522 12 payments
  6. DePuy Synthes Sales Inc. $468 20 payments
  7. Stryker Corporation $359 12 payments
  8. Bioventus LLC $244 7 payments
  9. Advanced Orthopaedic Solutions, Inc. $236 1 payment
  10. Treace Medical Concepts, Inc. $221 5 payments
  11. Other $845 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $53,786 10 payments
  2. Education $3,761 4 payments
  3. Food and Beverage $3,595 113 payments
  4. Travel and Lodging $2,243 8 payments
Products named General payments · program years 2019–2025
  1. Arsenal Ankle 10 Hole 1/3 Tubular Plate $53,786 10 payments
  2. HemiCAP $600 1 payment
  3. INFINITY $442 7 payments
  4. Tactoset $419 2 payments
  5. AOS PRODUCTS $236 1 payment
  6. LAPIPLASTY SYSTEM $202 4 payments
  7. TFN ADVANCED $180 7 payments
  8. EUFLEXXA $140 6 payments
  9. XIAFLEX $133 6 payments
  10. NA $116 3 payments
  11. Other $1,839 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

771

Median for Orthopedic Surgery: 203

Drug cost

$4,779

Median for Orthopedic Surgery: $1,433

Branded share of claims

24.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 148 $1,441
Celecoxib Generic 128 $875
Methylprednisolone Generic 114 $804
Meloxicam Generic 213 $519
Ketorolac Tromethamine Generic 11 $255
Ibuprofen Generic 26 $210
Acetaminophen-Codeine Acetaminophen With Codeine Brand 39 $202
Tramadol Hcl Generic 59 $177
Gabapentin Generic 21 $155
Diclofenac Sodium Generic 12 $141

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$110,392

Of which drugs: $10,705

Medicare patients

258

Average age 74

Services billed

1,599

174 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 32%
Chronic kidney disease 31%
Ischemic heart disease 28%
Depression 22%
Osteoporosis 20%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 12 22 $8,730
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 117 280 $1,481

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record